Latest Life Sciences News

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.

Vection Technologies has expanded its AI contract portfolio by securing an additional $2.1 million through a deepened exclusive partnership with Area12 Consulting, bringing total contracts since May 2025 to $5.7 million.

Synertec Corporation Limited reported an 8% revenue decline to $18.2 million in FY2025 alongside a $7.64 million net loss, yet its Engineering segment showed a strong EBITDA rebound and its Powerhouse renewable technology revenue nearly doubled.

EZZ Life Science Holdings Limited reported a slight increase in revenue for the year ended June 2025, while net profit experienced a modest decline. The company also boosted its net tangible assets per share and maintained steady dividend payments.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

AnteoTech Ltd reports a strong FY2025 with doubled sales revenue, strategic partnerships, and key product milestones in battery materials and life sciences diagnostics.

Trajan Group Holdings Limited reported a 7.4% increase in revenue to $166.5 million for FY25, marking a significant turnaround with a return to profit after tax attributable to owners of $2.2 million. The company also reduced net debt and improved EBITDA by 26.2%, driven by organic growth and strategic acquisitions.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

AnteoTech Ltd reported a 110% revenue increase to A$968,878 in FY2025 alongside a 24% reduction in net loss, driven by strategic cost savings and key partnerships. Leadership renewal and product validation position the company for growth in battery and life sciences markets.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Vita Life Sciences delivered a robust first half in 2025 with record revenue and profit growth, driven by strong performances in Australia and Southeast Asia. The company also raised its interim dividend and expanded marketing efforts.